» Articles » PMID: 31897130

Bioinformatics Analysis to Screen Key Genes in Papillary Thyroid Carcinoma

Overview
Journal Oncol Lett
Specialty Oncology
Date 2020 Jan 4
PMID 31897130
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma, and its incidence has been on the increase in recent years. However, the molecular mechanism of PTC is unclear and misdiagnosis remains a major issue. Therefore, the present study aimed to investigate this mechanism, and to identify key prognostic biomarkers. Integrated analysis was used to explore differentially expressed genes (DEGs) between PTC and healthy thyroid tissue. To investigate the functions and pathways associated with DEGs, Gene Ontology, pathway and protein-protein interaction (PPI) network analyses were performed. The predictive accuracy of DEGs was evaluated using the receiver operating characteristic (ROC) curve. Based on the four microarray datasets obtained from the Gene Expression Omnibus database, namely GSE33630, GSE27155, GSE3467 and GSE3678, a total of 153 DEGs were identified, including 66 upregulated and 87 downregulated DEGs in PTC compared with controls. These DEGs were significantly enriched in cancer-related pathways and the phosphoinositide 3-kinase-AKT signaling pathway. PPI network analysis screened out key genes, including acetyl-CoA carboxylase beta, cyclin D1, BCL2, and serpin peptidase inhibitor clade A member 1, which may serve important roles in PTC pathogenesis. ROC analysis revealed that these DEGs had excellent predictive performance, thus verifying their potential for clinical diagnosis. Taken together, the findings of the present study suggest that these genes and related pathways are involved in key events of PTC progression and facilitate the identification of prognostic biomarkers.

Citing Articles

Therapeutic targeting of TNIK in papillary thyroid carcinoma: a novel approach for tumor growth suppression.

Zhang R, Yu Y, Yang Y, Zhang M, Zhang X, Chang Y Med Oncol. 2024; 41(6):160.

PMID: 38763968 DOI: 10.1007/s12032-024-02380-y.


Identification of potential targetable genes in papillary, follicular, and anaplastic thyroid carcinoma using bioinformatics analysis.

Agarwal S, Gupta S, Raj R Endocrine. 2024; 86(1):255-267.

PMID: 38676768 DOI: 10.1007/s12020-024-03836-x.


TPO as an indicator of lymph node metastasis and recurrence in papillary thyroid carcinoma.

Li X, Cheng R Sci Rep. 2023; 13(1):10848.

PMID: 37407700 PMC: 10322834. DOI: 10.1038/s41598-023-37932-1.


Histone acetylation modifications: A potential targets for the diagnosis and treatment of papillary thyroid cancer.

Chen C, Liu J Front Oncol. 2022; 12:1053618.

PMID: 36523971 PMC: 9745171. DOI: 10.3389/fonc.2022.1053618.


MicroRNAs as the critical regulators of cell migration and invasion in thyroid cancer.

Hamidi A, Taghehchian N, Basirat Z, Zangouei A, Moghbeli M Biomark Res. 2022; 10(1):40.

PMID: 35659780 PMC: 9167543. DOI: 10.1186/s40364-022-00382-4.


References
1.
Shou X, Li Y, Hu W, Ye T, Wang G, Xu F . Six-gene Assay as a new biomarker in the blood of patients with colorectal cancer: establishment and clinical validation. Mol Oncol. 2018; 13(4):781-791. PMC: 6441906. DOI: 10.1002/1878-0261.12427. View

2.
Prasad N, Somervell H, Tufano R, Dackiw A, Marohn M, Califano J . Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res. 2008; 14(11):3327-37. PMC: 3086681. DOI: 10.1158/1078-0432.CCR-07-4495. View

3.
Min X, Huang P, Liu X, Dong C, Jiang X, Yuan Z . Bioinformatics analyses of significant prognostic risk markers for thyroid papillary carcinoma. Tumour Biol. 2015; 36(10):7457-63. DOI: 10.1007/s13277-015-3410-6. View

4.
Port M, Boltze C, Wang Y, Roper B, Meineke V, Abend M . A radiation-induced gene signature distinguishes post-Chernobyl from sporadic papillary thyroid cancers. Radiat Res. 2007; 168(6):639-49. DOI: 10.1667/RR0968.1. View

5.
Yang X, Hu Y, Shi H, Zhang C, Wang Z, Liu X . The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma. Eur Arch Otorhinolaryngol. 2018; 275(8):2127-2134. DOI: 10.1007/s00405-018-5045-x. View